ReviewCancer immunology, immunotherapy : CII2012
Novel insights into the molecular mechanisms of HLA class I abnormalities.
Review in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 74 citations in OpenAlex.
- Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5.Journal of translational medicine · 2025Article
- The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine.Frontiers in immunology · 2023Review
- Curcuphenol possesses an unusual histone deacetylase enhancing activity that counters immune escape in metastatic tumours.Frontiers in pharmacology · 2023Article
- Understanding the squamous cell carcinoma immune microenvironment.Frontiers in immunology · 2023Review
- Review
- Prognostic value of Dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer.Scientific reports · 2022Article
- Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma.International journal of oral science · 2021Review
- Investigating T Cell Immunity in Cancer: Achievements and Prospects.International journal of molecular sciences · 2021Review
- Review
- Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.Cancers · 2021Article
- Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma.Journal of clinical medicine · 2020Article
- HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer.Cancers · 2020Article
- Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients.Oncoimmunology · 2020Article
- NLRC5: new cancer buster?Molecular biology reports · 2020Review
- Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.Breast cancer research : BCR · 2019Article
- Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer.Cancer immunology, immunotherapy : CII · 2019Article
- Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Multiparametric immune profiling in HPV- oral squamous cell cancer.JCI insight · 2017Article
- Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.Therapeutic advances in vaccines · 2017Article
- NLRC5/CITA: A Key Player in Cancer Immune Surveillance.Trends in cancer · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations in the MHC class I surface antigens represent one mechanism of tumor cells to escape from natural or immunotherapy-induced antitumor immune responses. In order to restore MHC class I expression, knowledge about the underlying molecular mechanisms of MHC class I defects in different tumor types is required. In most cases, abnormalities of MHC class I expression are reversible by cytokines suggesting a deregulation rather than structural abnormalities of members of the antigen-processing and presentation machinery (APM). The impaired expression of APM components could be controlled at the epigenetic, transcriptional and/or posttranscriptional level. Furthermore, a direct link between altered transcription factor binding, interferon signal transduction and MHC class I APM component expression has been shown, which might be further associated with cell cycle progression. This information will not only give novel insights into the (patho) physiology of the antigen-processing and presenting pathway, but will help in the future to design effective T cell-based immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.